What are plasma biomarkers in Alzheimer's disease?

What they are

A plasma biomarker is something measurable in the blood that tells you something about a disease process happening inside the body. In Alzheimer's disease, plasma biomarkers are blood tests that measure proteins associated with the underlying brain pathology - most importantly, a phosphorylated form of the tau protein called p-tau217.

What makes this remarkable is that until very recently, confirming or ruling out Alzheimer's pathology required either a brain scan (amyloid PET) or a spinal-fluid test (lumbar puncture). Both work well. Both involve significant procedural friction. A blood draw does not.

Why this matters

Two related effects.

First, friction matters in real medical practice. A test that takes a phlebotomy chair and a few minutes is dramatically easier to order - and to act on - than a test that takes a PET scanner or a spinal tap. The cost is meaningfully lower as well.

Second, the eligible population for anti-amyloid treatment is defined in part by amyloid pathology being present. Easier and cheaper confirmation of that pathology means more patients can get a clear answer. We cover the downstream effects of this in our Insight on how blood biomarkers will reshape diagnosis.

What they actually measure

The clinically most useful plasma biomarker in 2026 is plasma phosphorylated tau 217 (plasma p-tau217). It correlates well with the underlying brain pathology that defines Alzheimer's disease - specifically with both amyloid burden as measured by PET and with later tau pathology.

Other plasma biomarkers in clinical use include the plasma Aβ42/40 ratio (a measure related to amyloid biology) and additional tau-related markers (such as p-tau181, MTBR-tau243). The relative role of each continues to evolve.

How they are used in practice

In US clinical practice in 2026, plasma p-tau217 is most commonly used as a triage step. The flow looks like this:

• A patient with cognitive symptoms is evaluated by a clinician.
• If the clinical picture suggests Alzheimer's might be the cause, plasma p-tau217 testing can support - or argue against - that hypothesis.
• A clearly negative result reduces the probability that Alzheimer's pathology is driving the symptoms, often without needing a PET or CSF confirmation.
• A clearly positive result raises the probability that Alzheimer's pathology is present, often supporting confirmation by amyloid PET or CSF before starting disease-modifying treatment.
• Equivocal results are interpreted in the clinical context, sometimes leading to confirmatory testing.

The exact way plasma testing fits into a workflow varies by health system and by individual clinician. Adoption is uneven, and we cover that geography in our Signal on plasma-biomarker access.

What they cannot tell you

Plasma biomarkers tell you something about the probability of Alzheimer's pathology being present. They do not, on their own:

• Diagnose Alzheimer's disease as a clinical condition. Cognitive symptoms have many possible causes.
• Predict how fast a person's symptoms will progress.
• Replace the careful clinical evaluation - history, examination, cognitive assessment - that anchors any reasonable diagnostic process.

Practical considerations

A few things matter when interpreting a plasma biomarker result:

• Pre-analytical handling - how the blood is collected, handled, and stored - matters more than for routine clinical chemistry. Reputable labs have validated protocols for this.
• The performance of the assay can vary across populations not well represented in the original validation cohorts. The clinical interpretation should reflect this.
• The test is not the whole answer. The clinician's overall clinical assessment is.

What this means in practice

If a clinician has ordered a plasma biomarker test, it is usually because they want to know whether Alzheimer's pathology is contributing to cognitive symptoms. The result is one input into a clinical decision - typically a more accessible input than a PET scan or a lumbar puncture, but still one input among several.

This page is a plain-language primer. It is not medical advice. Decisions about diagnostic testing belong with the patient and their clinician.